New use for BladderChek test imminent:
This article was originally published in Clinica
Executive Summary
Matritech has moved closer in the US to expanding the use of its 30-minute, doctor's office bladder cancer test, after the FDA deemed the test approvable for helping to diagnose the disease. The NMP22 BladderChek test was cleared last year for monitoring patients previously diagnosed with bladder cancer. Permission for the expanded indication depends on the successful completion of a routine manufacturing facility inspection, which the Newton, Massachusetts firm expects "to be completed promptly".
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.